Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Wiernik, P. H.
Lossos, I. S.
Tuscano, J.
Justice, G.
Vose, J. M.
Pietronigro, D.
Takeshita, K.
Ervin-Haynes, A.
Zeldis, J.
Habermann, T.
机构：
[1] New York Med Coll, Bronx, NY USA
[2] Univ Miami, Miami, FL USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[4] Pacific Coast Hematol Oncol Med Grp, Fountain Valley, CA USA
[5] Univ Nebraska, Omaha, NE 68182 USA
[6] Celgene Corp, Summit, NJ USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8052
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [32] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [33] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
    Josting, A
    Sieniawski, M
    Staak, J
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
  • [34] Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
    Witzig, Thomas E.
    Vose, Julie M.
    Zinzani, Pier Luigi
    Reeder, Craig B.
    Buckstein, Rena
    Polikoff, Jonathan
    Guo, Pingshan
    Pietronigro, Dennis
    Ervin-Haynes, Annette
    Czuczman, Myron S.
    BLOOD, 2009, 114 (22) : 668 - 669
  • [35] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [36] The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
    Czuczman, Myron S.
    Vose, Julie M.
    Witzig, Thomas E.
    Zinzani, Pier L.
    Buckstein, Rena
    Polikoff, Jonathan
    Li, Ju
    Pietronigro, Dennis
    Ervin-Haynes, Annetti
    Reeder, Craig B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (04) : 477 - 481
  • [37] Lenalidomide oral monotherapy produces a 53% response rate in patients with relapsed/refractory mantle-cell non-Hodgkin's lymphoma
    Tuscano, Joseph M.
    Lossos, Izidore S.
    Justice, Glen
    Vose, Julie M.
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Pietronigro, Dennis
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2007, 110 (11) : 755A - 755A
  • [38] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [39] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
    Gillian M. Keating
    Drugs, 2016, 76 : 1579 - 1586
  • [40] Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Weidmann, E
    Kim, SZ
    Rost, A
    Schuppert, H
    Seipelt, G
    Hoelzer, D
    Mitrou, PS
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1285 - 1289
12345